EpiCast Report Venous Thromboembolism Epidemiology Forecast to 2026
ReportsWeb.com published “Venous Thromboembolism Epidemiology Market” from its
database. The report covers the market landscape and its growth prospects over the coming
years. The report also includes a discussion of the key vendors operating in this market.
Venous thromboembolism (VTE) , which is composed of deep vein thrombosis (DVT) and
pulmonary embolism (PE) , is a blood clot (thrombosis) of the circulatory system that leads to
impeded blood flow, which can have serious consequences in affected individuals. VTE can
occur at any age, but it is more common in adults ages 60 years and older and is very rare in
children. VTE events are highly dangerous and are associated with high rates of mortality and
morbidity.
Publisher epidemiologists forecast an increase in the diagnosed incident cases of VTE in the
seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) , from 896,377
cases in 2016 to 1,071,438 in 2026, at an Annual Growth Rate (AGR) of 1.95%.The number of
VTE attacks is forecast to grow from 1,020,991 in 2016 to 1,224,696 in 2026 in the 7MM.
Publisher epidemiologists have identified the predominant drivers of this market to be changes
in country-specific incidence and procedure rates, as well as in the underlying demographic
trends.
For more information about this report: http://www.reportsweb.com/epicast-report-venous-
thromboembolism-epidemiology-forecast-to-2026
Publisher epidemiologists forecast the prevalent cases of VTE in the 7MM from 2016-2026
using nationally-representative, country-specific studies published in peer-reviewed journals
that provided the age- and sex-specific incidence of VTE, DVT, and PE in the 7MM. Additionally,
they forecast the number of VTE attacks, medically ill discharges at risk of VTE, knee and hip
replacements, recurrent VTE cases at one and 10 years, and VTE cases with cancer as
comorbidity. Publisher epidemiologists ensured that the forecast methodology was consistent
across all the 7MM to allow for a meaningful comparison of the diagnosed incident cases of VTE
across these markets.